FIELD: medicine.
SUBSTANCE: probiotic strain of Enterococcus faecium L-3 is used. Therapy is carried out by short courses (up to a month) with interruptions under the control of the intestinal microbiota composition and the populations of circulating T cells. In case of exacerbations, traditional therapy with copaxone can be used (the use of a probiotic should be stopped for this period).
EFFECT: method allows to increase the effectiveness of treatment by stimulating the production of anti-inflammatory cytokine.
5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREPARING AN AUTOPROBIOTIC BASED ON AN ANAEROBIC CONSORTIUM OF BACTERIA | 2018 |
|
RU2734896C2 |
| METHOD OF REDUCING MANIFESTATION OF NON-MOTOR SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE | 2019 |
|
RU2734718C1 |
| METHOD OF THERAPY OF REMITTENT MULTIPLE SCLEROSIS | 2012 |
|
RU2523058C2 |
| METHOD FOR MONOTHERAPY OF GASTRITIS ASSOCIATED WITH HELICOBACTER PYLORI INFECTION | 2020 |
|
RU2758246C1 |
| METHOD FOR LYMPHOSTIMULATION AND IMMUNOMODULATION IN CEREBROSPINAL SCLEROSIS | 2003 |
|
RU2246942C2 |
| ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS BASED ON BACTERIAL STRAIN | 2015 |
|
RU2616899C1 |
| METHOD FOR TREATING THE CASES OF DISSEMINATED SCLEROSIS | 2001 |
|
RU2214839C2 |
| TEST MODEL FOR INVESTIGATING ACTION OF DRUGS WHICH PREVENT DEMYELINATION, METHOD FOR PREPARING AND USING THEREOF | 2019 |
|
RU2736070C1 |
| SOLID ORAL PHARMACEUTICAL COMPOSITION OF S1P AGONIST OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR ITS PRODUCTION AND METHODS FOR TREATMENT AND REDUCTION OF FREQUENCY OF CLINICAL EXACERBATIONS OF MULTIPLE SCLEROSIS | 2015 |
|
RU2639424C2 |
| METHOD FOR CORRECTION OF COMPOSITION OF INTESTINAL MICROFLORA IN CHILDREN | 2022 |
|
RU2801611C1 |
